News | Contrast Media | September 12, 2017

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

Medical Imaging Drugs Advisory Committee (MIDAC) votes 13 to 1 to add warning of the possible risks of gadolinium retention

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly last week to recommend new labels on gadolinium-based contrast agents (GBCAs) warning of the possibility of gadolinium retention in the body following administration during magnetic resonance imaging (MRI) exams. The labels will further explain that linear GBCAs carry a greater risk than macrocyclic agents, and that there is a greater risk for certain patient populations, according to Medscape.

The meeting, held Sept. 8, brought FDA officials together with healthcare professionals, industry representatives, patients and patient advocacy groups to discuss the merit of changing the regulatory approach for GBCAs. Representatives from Guerbet, Bayer, Bracco and GE Healthcare were all present at the meeting.

Concerns have emerged about gadolinium-based contrast agents in recent years as research has suggested that gadolinium is retained in the body, particularly in the brain, after administration and could cause adverse health effects, particularly for patients with renal failure. The FDA issued a Drug Safety Communication in May 2017 titled “No Harmful Effects Identified With Brain Retention,” in which the agency said it had not identified any adverse health effects from gadolinium retained in the brain, but that it would continue its review. 

In a statement released before the Sept. 8 meeting, the FDA said, “FDA’s approach has been educational: alerting the public and clinicians to the retention phenomenon but not issuing any restrictions on use because toxic effects in humans have not been established.”

For more information: www.fda.gov

 

Related Content on MRI Gadolinium Retention in the Brain

FDA: No Harm in MRI Gadolinium Retention in the Brain

Recent Trends and Developments in Contrast Media

VIDEO: MRI Gadolinium Contrast Retention in the Brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
News | Imaging | September 11, 2017
September 11, 2017 — Innovatus Imaging Corp., a newly created holding company formed by private equity firm Resilienc
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
CIRS Launches New MRI Distortion Check Software
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
MRI Distortion Check is a new, cloud-based solution designed to quickly and automatically quantify distortion in...
FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S.
Study Assesses Usefulness of MRI for Pediatric Sports-Related Concussion
News | Neuro Imaging | September 05, 2017
September 5, 2017 — A new study reviewed more than 5 years of records of...
The GE Healthcare Signa Premier MRI was among the top radiology stories from August 2017

The GE Healthcare Signa Premier MRI was among the top radiology stories from August 2017.

Feature | Imaging | September 01, 2017 | Melinda Taschetta-Millane
Here is the list of the most popular articles and videos on the Imaging Technology News (ITN) magazine website from the...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Overlay Init